STOCK TITAN
  1. Home
  2. News
  3. BLUE

Bluebird bio Inc - BLUE STOCK NEWS

Welcome to our dedicated news page for Bluebird bio (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bluebird bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bluebird bio's position in the market.

News
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
-
News
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) reported fourth quarter and annual financial results for 2023, highlighting a $175 million term loan facility with Hercules Capital extending cash runway through Q1 2026. The Company anticipates 85 to 105 patient starts in 2024 across its gene therapy portfolio, with a focus on LYFGENIA for sickle cell disease. Recent commercial progress includes government outcomes-based agreement with Michigan Medicaid and activation of 62 Qualified Treatment Centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
News
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
Rhea-AI Summary
bluebird bio, Inc. (BLUE) will host a conference call on March 26, 2024, to discuss Q4 and 2023 annual results and business updates. The call can be accessed via telephone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
News
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
Rhea-AI Summary
bluebird bio secures a $175 million term loan facility with Hercules Capital, extending its cash runway for up to 24 months. The company draws the first tranche of $75 million with the potential to access an additional $50 million based on commercial milestones. This funding aims to support the commercial launches of its FDA-approved gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
News
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announces its first Medicaid outcomes-based agreement for LYFGENIA gene therapy with Michigan, aiming to provide timely access to sickle cell disease patients. The agreement reflects the company's commitment to equitable access and value-based contracting approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
none
-
News
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) announced updates at the 42nd Annual J.P. Morgan Healthcare conference, including commercial launch progress, 2024 program milestones, and financial outlook. LYFGENIA is expected to have 85 to 105 patient starts in 2024, with the first patient start in Q1 2024. The company's cash, cash equivalents, and marketable securities are expected to fund current operations into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.52%
Tags
none
News
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) CEO to Present Corporate Update at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
conferences
-
News
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, with expected gross proceeds of $125 million. The company plans to use the net proceeds to support commercialization and manufacturing for its approved gene therapies and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.68%
Tags
offering
-
News
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has announced a public offering of $150,000,000 of its common stock, with an option for underwriters to purchase an additional $22,500,000. The offering will support commercialization and manufacturing of its three approved gene therapies, ZYNTEGLO, SKYSONA, and LYFGENIA, as well as fund working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.33%
Tags
offering
News
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Rhea-AI Summary
bluebird bio inc. (NASDAQ: BLUE) presented updated data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, showing sustained transfusion independence and improvements in iron management in patients with transfusion-dependent beta-thalassemia treated with beti-cel. The data demonstrated durable transfusion independence and a continued positive safety profile in patients through up to nine years of follow-up, reflecting beti-cel's potential as a curative therapy. A total of 63 patients across four clinical studies received beti-cel, with 90.2% of patients in the Phase 3 studies achieving transfusion independence. The safety results following beti-cel treatment largely reflected known side effects, with 19% of patients experiencing beti-cel-related adverse events. Iron management outcomes showed that 69% of patients were able to stop chelation therapy, demonstrating reduced iron management burden in those patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock BLUE logo
Bluebird bio Inc

Nasdaq:BLUE

BLUE Rankings

#3817 Ranked by Market Cap
#4831 Ranked by Stock Gains
N/A Ranked by Dividends

BLUE Stock Data

190.87M
108.82M
0.38%
65.11%
15.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Somerville

About BLUE

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.